Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Https://www.lse.co.uk/rns/HE1/itumbula-west-1-well-flows-helium47-to-surface-h3ozbl2v33bohu1.html
My understanding was that the next RNS would be a more detailed lab appraisal above, confirming the find?
Is this still the case, and if so what timescales are we looking at?
Best wishes,
Stephen11.
Ps…and please, no conspiracy theorists.
Its up if you want to buy on HL
SP up aswell on open!
0.42 to buy and +7% up on HL
GLA.
Stephen11.
**Stroke Test - CYP2CI9**
- The CYP2CI9 test is being actively marketed around Europe as a research only product - to create interest around the various countries and to create early commercial traction
- A US peer reviewed study has shown that hospitilisation from an adverse reaction to Clipidogrel costs on average $8 to $20 thousand dollars per person - the CYP2CI9 test would eradicate this cost
GLA.
Stephen11.
You only ever post on GDR, although you don’t appear to be a shareholder.
If this share is such a dog, please enlighten us all to your investing strategy? What’s on your watchlist at the moment, why are the fundamentals of said companies strong, and why might the SP rise?
Have a great day 😀.
Stephen11.
Ps…can wait to hear from you…the new Warren Buffet of AIM
Also Allguessing,
GDR is unlike any business that has been on Dragons Den - the NHS and the various health care bodies around the world are amongst the most highly regulated organisations in the world. It's not like trying to sell something online.
Stephen11.
Let's not forget that the MTRNR1 test can and has saved children from lifelong hearing loss as it prevents adverse drug reactions from certain medications that premature babies may require. The test allows for an alternative and more suitable medication to be administered within a speedy, yet critical time frame. It's also the only test of its kind in the world.
I'm also thinking that irrespective of full NICE accreditation or Specialist Commissioning (which i hope happens) we may see a type of de-facto adoption when between 5 and 10 NHS Trusts acquire the test around the UK. Evidence of this is starting to emerge.
Let's think about this!?
If Manchester, Brighton, Edinburgh, and Belfast Trusts were saving children from lifelong hearing loss it would be extremely unfair if premature babies from neighboring Trusts (Liverpool, Kent, Glasgow, or Craigavon) didn't have access to the same test. In this sense after a certain amount of adoption and success, the test should sell itself.
GLA.
Stephen11
Approximately what date will the AGM be?
Thanks
Thanks Jimi - how could i forget a region with a GDP of $896 billion (2023)...lol.
- United Arab Emirates (UAE): Babirus
- Turkey: Ertunc Ozcan
- Greece: Artisel
- Kuwait: Al Essa
- France: Eurocare
- Saudi Arabia: ideal idea
- Austria: Connect Medizintechnik GmbH
- Spain: PRHOINSA
- UK: Inspiration Healthcare (as we already know)
- The Netherlands
- Italy: Burke and Burke
I'd like to think a few of these countries would produce commercial traction soon!
Saudi Arabia is also an extremely lucrative market for private health care, especially with all the foreign workers and families in the likes of the oil and petro-chemical industries.
GLA.
Stephen11.
Here's the list of distributors i had previously:
- Turkey: Ertunc Ozcan
- Greece: Artisel
- Kuwait: Al Essa
- France: Eurocare
- Saudi Arabia: ideal idea
- Austria: Connect Medizintechnik GmbH
- Spain: PRHOINSA
- UK: Inspiration Healthcare (as we already know)
- The Netherlands
- Italy: Burke and Burke
I'd like to think a few of these countries would produce commercial traction soon!
Saudi Arabia is also an extremely lucrative market for private health care, especially with all the foreign workers and families in the likes of the oil and petro-chemical industries.
GLA.
Stephen11.
Ps....have i missed any countries?
You've changed your tune - you were advising people to buy GDR at £1.27. Your own words below:
"Most of the weak investors who didn’t have the b**** to wait have been dumped following the last RNS, don’t take your chances and buy in now. RNS imminent...share price is expected to fly. Saw an interesting article from professor A.Khan a few weeks ago, but can’t seem to find the link."